Daniel Kelly is a senior lecturer in Biochemistry at Sheffield Hallam University with research interests in cardiovascular disease, type 2 diabetes, obesity and the role of testosterone in these diseases. Following his PhD studying the anti-inflammatory effects of testosterone on atherosclerosis, Daniel undertook a postdoc at the University of Sheffield to work with Professor Hugh Jones to investigate the tissue-specific actions of testosterone related to the pathogenesis of type 2 diabetes and cardiovascular disease. This research continues at Sheffield Hallam University and extends through on-going collaborations with partners at the University of Sheffield, University of Chile, Barnsley NHS foundation trust and Bayer Healthcare where he is currently using cell culture systems, pre-clinical models and medical trials of replacement therapy to uncover the underlying mechanisms of testosterone action. He has published in several high-impact journals in the field of endocrinology and acts as a reviewer for many of these journals. He is associate editor for the journal Androgens:Clinical research and Therapeutics.
Daniel has an honorary lectureship position at the University of Sheffield allowing close collaboration across the Sheffield Universities. He is the deputy course leader for the undergraduate Biomedical Science degree at Sheffield Hallam University where he uses his current and prior research to inform his teaching in areas related to metabolism, endocrinology, cell biology, and biological basis of disease.
Experience
2018–present
Senior lecturer, Sheffield Hallam University
2016–2018
Lecturer, Sheffield Hallam University
2011–2016
Postdoctoral research associate, Univesity of Sheffield
Education
2010
Sheffield Hallam University, PhD
2003
Aston University, Birmingham, BSc (hons) Human Biology and Psychology
Publications
2023
Testosterone treatment and change of categories of the International prostate symptom score (IPSS) in hypogonadal patients: 12 years prospective controlled registry study, Aging Male
2023
Testosterone and Covid-19: An update, Reviews in Medical Virology
2023
Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate size, International Journal of Nephrology
2022
COVID-19 Crisis Timeline: The Warning and the Surge, Health Crisis Management in Acute Care Hospitals
2022
The effects of long-term testosterone treatment on endocrine parameters in hypogonadal men: 12-year data from a prospective controlled registry study, Aging Male
2021
Testosterone stimulates cholesterol clearance from human macrophages by activating LXRalpha, Life Sciences
2021
Sex-based differences in severity and mortality in COVID-19, Reviews in Medical Virology
2020
Long-term testosterone therapy improves liver parameters and steatosis in hypogonadal men: a prospective controlled registry study, Aging Male
2018
Randomized controlled trials - mechanistic studies of testosterone and the cardiovascular system., Asian Journal Andrology
2016
Testosterone differentially regulates targets of lipid and glucose metabolism in liver, muscle and adipose tissue of the testicular feminised mouse., Endocrine
2015
Testosterone and Obesity., Obesity Reviews
2014
Testosterone suppresses regulatory enzymes of fatty acid synthesis and protects against hepatic steatosis in cholesterol-fed androgen deficient mice. , Life Sciences
2014
Testosterone and cardiovascular risk in men., Vol. 43 Frontiers of Hormone Research
2013
Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. , Nature Reviews Endocrinology
2013
Testosterone: A Metabolic Hormone in Health and Disease., Journal of Endocrinology
2013
Testosterone: A Vascular Hormone in Health and Disease., Journal of Endocrinology
2012
Effect of Testosterone on Inflammatory Markers in the Development of Early Atherogenesis in the Testicular-Feminized Mouse Model., Endocrine Research